|
41 Companies |
|
29 Products |
|
29 Products |
|
22 Mechanisms of Action |
|
2 Trials |
|
854 News |
|
| 12345678910111213...1617» |
- | amphotericin b liposome / Generic mfg.
Trial completion, Enrollment change, Combination therapy, Monotherapy: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (clinicaltrials.gov) - Apr 20, 2019
P3, N=59, Completed, Sponsor: Drugs for Neglected Diseases
Active, not recruiting --> Completed | N=132 --> 59
- | Trial completion: Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram (clinicaltrials.gov) - Mar 13, 2019
P=N/A, N=327, Completed, Sponsor: Olive View-UCLA Education & Research Institute
Active, not recruiting --> Completed | N=132 --> 59 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2) (clinicaltrials.gov) - Mar 5, 2019
P3, N=200, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> May 2016 | Trial primary completion date: Aug 2018 --> May 2016
- | Trial completion, Trial completion date, Trial primary completion date: Safer Sex Program for Young African-American Men (clinicaltrials.gov) - Feb 21, 2019
P2, N=620, Completed, Sponsor: Richard Crosby
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> May 2016 | Trial primary completion date: Aug 2018 --> May 2016 Recruiting --> Completed | Trial completion date: May 2019 --> Apr 2018 | Trial primary completion date: May 2018 --> Nov 2017
- | Trial termination: Papua New Guinean Duffy Negativity And Vivax Malar (clinicaltrials.gov) - Feb 4, 2019
P=N/A, N=266, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial completion date: May 2019 --> Apr 2018 | Trial primary completion date: May 2018 --> Nov 2017 Suspended --> Terminated
- | Trial completion, Enrollment change: Malaria Transmission and Immunity in Highland Kenya (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=20610, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Suspended --> Terminated Recruiting --> Completed | N=6400 --> 20610
- | Trial completion: Malaria Prevalence in Children (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=2552, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=6400 --> 20610 Recruiting --> Completed
- | Trial completion, Enrollment change: Time to Infection With Malaria Parasites (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=2558, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Recruiting --> Completed | N=552 --> 2558
- | Trial completion, Enrollment change: Fetal Immunity to Falciparum Malaria (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=500, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=552 --> 2558 Recruiting --> Completed | N=1020 --> 500
- | Trial completion: Plasmodium Resistance in A. Gambiae (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=1020 --> 500 Recruiting --> Completed
- | sulfadoxine/pyrimethamine / Generic mfg.
Enrollment change: SP Resistance and Falciparum Malaria Transmission (clinicaltrials.gov) - Jan 30, 2019
P3, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=150 --> 0
- | Enrollment change: CS DNA MVA Trial in Mampong, Ghana (clinicaltrials.gov) - Jan 23, 2019
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=150 --> 0 N=48 --> 0
- | chloroquine phosphate / Generic mfg., primaquine / Generic mfg.
Trial completion: Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan (clinicaltrials.gov) - Jan 16, 2019
P4, N=593, Completed, Sponsor: University of Oxford
N=48 --> 0 Recruiting --> Completed
- | chloroquine phosphate / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Chloroquine Population Pharmacokinetics in Pre and Post-partum Women (clinicaltrials.gov) - Jan 8, 2019
P=N/A, N=49, Completed, Sponsor: University of Oxford
Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2019 --> May 2017 | Trial primary completion date: Sep 2019 --> Nov 2016
- | Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi, NN1213 / Novo Nordisk, Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Trial completion date: Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali (clinicaltrials.gov) - Oct 24, 2018
P1, N=538, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Sep 2019 --> May 2017 | Trial primary completion date: Sep 2019 --> Nov 2016 Trial completion date: Nov 2017 --> Oct 2018
- | chloroquine phosphate / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Chloroquine Population Pharmacokinetics in Pre and Post-partum Women (clinicaltrials.gov) - Oct 3, 2018
P=N/A, N=50, Active, not recruiting, Sponsor: University of Oxford
Trial completion date: Nov 2017 --> Oct 2018 Recruiting --> Active, not recruiting | N=160 --> 50 | Trial completion date: Dec 2017 --> Sep 2019 | Trial primary completion date: Dec 2017 --> Sep 2019
- | Enrollment change: Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia (clinicaltrials.gov) - Aug 31, 2018
P2/3, N=0, Withdrawn, Sponsor: University of Oxford
Recruiting --> Active, not recruiting | N=160 --> 50 | Trial completion date: Dec 2017 --> Sep 2019 | Trial primary completion date: Dec 2017 --> Sep 2019 N=75 --> 0
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: DRIPICCO: Optimal Fluid Management in Adult Severe Malaria (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=156, Completed, Sponsor: University of Oxford
N=75 --> 0 Recruiting --> Completed | N=120 --> 156 | Trial completion date: Dec 2015 --> Dec 2017 | Trial primary completion date: Dec 2015 --> Dec 2017
- | NN1213 / Novo Nordisk
Trial completion: Malaria in Early Life Study (clinicaltrials.gov) - Aug 2, 2018
P=N/A, N=757, Completed, Sponsor: Gadjah Mada University
Recruiting --> Completed | N=120 --> 156 | Trial completion date: Dec 2015 --> Dec 2017 | Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Phase classification: Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib (clinicaltrials.gov) - Jul 18, 2018
P1a/1b, N=56, Completed, Sponsor: Centre Hospitalier Universitaire Vaudois
Recruiting --> Completed Phase classification: P1 --> P1a/1b
- | Phase classification: Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children (clinicaltrials.gov) - Jul 13, 2018
P=N/A, N=7680, Completed, Sponsor: University of California, Davis
Phase classification: P1 --> P1a/1b Phase classification: P4 --> P=N/A
- | Trial completion: Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria (clinicaltrials.gov) - Jun 14, 2018
P=N/A, N=62, Completed, Sponsor: University of Oxford
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed
- | Trial completion, Enrollment change: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis (clinicaltrials.gov) - Jun 2, 2018
P3, N=72, Completed, Sponsor: Oswaldo Cruz Foundation
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=264 --> 72
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: SR-M-IDR: Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia (clinicaltrials.gov) - May 3, 2018
P=N/A, N=1519, Completed, Sponsor: University of Notre Dame
Active, not recruiting --> Completed | N=264 --> 72 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018
- | Phase classification: Malaria Studies in Cambodia (clinicaltrials.gov) - Apr 6, 2018
P, N=1978, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 Phase classification: P=N/A --> P
- | Phase classification: Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia (clinicaltrials.gov) - Apr 6, 2018
P, N=415, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P Phase classification: P=N/A --> P
- | Phase classification, Enrollment change: Artemisinin-resistant Malaria in Cambodia (clinicaltrials.gov) - Apr 6, 2018
P, N=561, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P Phase classification: P=N/A --> P | N=860 --> 561
- | Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Enrollment change: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Apr 5, 2018
P1, N=230, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P | N=860 --> 561 N=350 --> 230
- | trimethoprim/sulfamethoxazole / Generic mfg.
Phase classification, Enrollment change: Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda (clinicaltrials.gov) - Apr 5, 2018
P, N=173, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=350 --> 230 Phase classification: P=N/A --> P | N=400 --> 173
- | Phase classification: Malaria Transmission Studies in Mali (clinicaltrials.gov) - Apr 5, 2018
P, N=534, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P | N=400 --> 173 Phase classification: P=N/A --> P
- | Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi, Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Enrollment change: Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali (clinicaltrials.gov) - Apr 5, 2018
P1, N=538, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P=N/A --> P N=54 --> 538
- | Trial completion, Trial completion date: Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax (clinicaltrials.gov) - Mar 23, 2018
P2, N=32, Completed, Sponsor: Malaria Vaccine and Drug Development Center
N=54 --> 538 Not yet recruiting --> Completed | Trial completion date: Aug 2015 --> Jul 2017
- | azithromycin / Generic mfg.
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: SMCAZ: A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children (clinicaltrials.gov) - Mar 7, 2018
P3, N=22090, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Not yet recruiting --> Completed | Trial completion date: Aug 2015 --> Jul 2017 Not yet recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2017 | Initiation date: Aug 2014 --> May 2014 | Trial primary completion date: Dec 2016 --> Dec 2017
- | Fexinidazole Winthrop (fexinidazole) / Sanofi, Lampit (nifurtimox) / Bayer
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Head-to-Head: Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 (clinicaltrials.gov) - Feb 20, 2018
P2/3, N=394, Completed, Sponsor: Drugs for Neglected Diseases
Not yet recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2017 | Initiation date: Aug 2014 --> May 2014 | Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | Trial completion date: Apr 2017 --> Apr 2017 | Initiation date: Nov 2012 --> Oct 2012 | Trial primary completion date: Oct 2016 --> Nov 2016
- | sodium valproate / Generic mfg.
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (clinicaltrials.gov) - Feb 14, 2018
P4, N=109, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed | Trial completion date: Apr 2017 --> Apr 2017 | Initiation date: Nov 2012 --> Oct 2012 | Trial primary completion date: Oct 2016 --> Nov 2016 Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Dec 2017 | Initiation date: Mar 2013 --> Apr 2013 | Trial primary completion date: Oct 2017 --> Oct 2017
- | Trial initiation date, Trial primary completion date: Improving Blood Safety and HIV Testing in Brazil (clinicaltrials.gov) - Jan 18, 2018
P=N/A, N=11900, Completed, Sponsor: Blood Systems Research Institute
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Dec 2017 | Initiation date: Mar 2013 --> Apr 2013 | Trial primary completion date: Oct 2017 --> Oct 2017 Initiation date: Mar 2012 --> Aug 2012 | Trial primary completion date: Sep 2013 --> May 2013
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Enrollment change, Combination therapy, Adherence: Adherence to Antimalarial Drugs in Sierra Leone (clinicaltrials.gov) - Jan 11, 2018
P=N/A, N=1145, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Initiation date: Mar 2012 --> Aug 2012 | Trial primary completion date: Sep 2013 --> May 2013 N=792 --> 1145
- | hydroxyurea / Generic mfg.
Trial completion: NOHARM: Novel Use Of Hydroxyurea in an African Region With Malaria (clinicaltrials.gov) - Nov 28, 2017
P3, N=208, Completed, Sponsor: Indiana University
N=792 --> 1145 Active, not recruiting --> Completed
- | Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi, Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Trial completion: Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali (clinicaltrials.gov) - Nov 6, 2017
P1, N=54, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events (clinicaltrials.gov) - Nov 1, 2017
P=N/A, N=208, Completed, Sponsor: Cornell University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Na (clinicaltrials.gov) - Oct 13, 2017
P1, N=39, Completed, Sponsor: U.S. Army Medical Research and Materiel Command
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2019 --> Jun 2015
- Enrollment change, Trial termination: Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays (clinicaltrials.gov) - Aug 16, 2017
P=N/A, N=1336, Terminated, Sponsor: Gen-Probe, Incorporated
Active, not recruiting --> Completed | Trial primary completion date: Aug 2019 --> Jun 2015 N=2100 --> 1336 | Active, not recruiting --> Terminated; Corporate decision to spend money on other development programs.
- | Trial completion, Trial initiation date, Trial primary completion date: Trichomonas Vaginalis Repeat Infections Among HIV Negative Women (clinicaltrials.gov) - Aug 4, 2017
P3, N=623, Completed, Sponsor: Tulane University Health Sciences Center
N=2100 --> 1336 | Active, not recruiting --> Terminated; Corporate decision to spend money on other development programs. Recruiting --> Completed | Initiation date: Jun 2013 --> Oct 2014 | Trial primary completion date: Dec 2017 --> Jun 2017
- | chloroquine phosphate / Generic mfg., artemether/lumefantrine / Generic mfg.
Trial completion: P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine (clinicaltrials.gov) - Jul 7, 2017
P3, N=123, Completed, Sponsor: Menzies School of Health Research
Recruiting --> Completed | Initiation date: Jun 2013 --> Oct 2014 | Trial primary completion date: Dec 2017 --> Jun 2017 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Experimental Vaccine for Malaria (clinicaltrials.gov) - Jun 30, 2017
P1, N=13, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
Enrollment change, Trial termination: Eurartesim (clinicaltrials.gov) - Jun 15, 2017
P2, N=27, Terminated, Sponsor: sigma-tau i.f.r. S.p.A.
Active, not recruiting --> Completed N=100 --> 27 | Recruiting --> Terminated; Low recruitment
- | NN1213 / Novo Nordisk
Enrollment change, Trial termination: Parasitic Infections of the Gastrointestinal Tract (clinicaltrials.gov) - Jun 2, 2017
P=N/A, N=150, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=100 --> 27 | Recruiting --> Terminated; Low recruitment N=200 --> 150 | Recruiting --> Terminated
- | Trial completion, Trial primary completion date: CM_CCRT: Computerized Cognitive Rehabilitation in Children After Severe Malaria (clinicaltrials.gov) - May 22, 2017
P=N/A, N=300, Completed, Sponsor: Makerere University
N=200 --> 150 | Recruiting --> Terminated Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Aug 2016
- | Trial completion: Auranofin PK Following Oral Dose Administration (clinicaltrials.gov) - Apr 28, 2017
P1, N=15, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Aug 2016 Recruiting --> Completed
- || Mosquirix (RTS,S) / GSK
Trial primary completion date: Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen (clinicaltrials.gov) - Apr 25, 2017
P2, N=511, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Trial primary completion date: Oct 2009 --> Sep 2008